Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Signaturefd LLC

Signaturefd LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 23.1% during the fourth quarter, HoldingsChannel reports. The firm owned 1,626 shares of the life sciences company’s stock after buying an additional 305 shares during the period. Signaturefd LLC’s holdings in Illumina were worth $226,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Illumina in the third quarter valued at $30,000. VisionPoint Advisory Group LLC boosted its holdings in shares of Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in shares of Illumina in the fourth quarter valued at about $37,000. Gradient Investments LLC boosted its holdings in shares of Illumina by 375.0% in the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after acquiring an additional 225 shares in the last quarter. Finally, North Star Investment Management Corp. boosted its holdings in shares of Illumina by 183.0% in the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after acquiring an additional 194 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 1.0 %

Shares of NASDAQ ILMN opened at $122.28 on Friday. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $213.91. The company has a market capitalization of $19.47 billion, a PE ratio of -16.66 and a beta of 1.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The firm’s 50-day moving average is $131.51 and its two-hundred day moving average is $127.31.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the firm earned $0.14 earnings per share. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Barclays lifted their target price on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. TD Cowen downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a report on Thursday, January 4th. Finally, OTR Global reissued a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $167.70.

Insider Activity

In other news, CEO Jacob Thaysen acquired 7,330 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.17% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.